

CITATION REPORT

List of articles citing

The Pharmacokinetic Profile of Tamsulosin Oral Controlled Absorption System (OCAS)

DOI: 10.1016/j.eursup.2004.11.002
European Urology Supplements, 2005, 4, 15-24.

Source: <https://exaly.com/paper-pdf/39130987/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
48	[Drug therapy for benign prostatic hyperplasia. Systematic overview]. <i>Der Urologe</i> , 2005 , 44, 505-12		2
47	Tamsulosin Oral Controlled Absorption System (OCAS) in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): Efficacy and Tolerability in a Phase 2b Dose-Response Study. <i>European Urology Supplements</i> , 2005 , 4, 25-32	0.9	12
46	Tamsulosin Oral Controlled Absorption System (OCAS) in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): Efficacy and Tolerability in a Placebo and Active Comparator Controlled Phase 3a Study. <i>European Urology Supplements</i> , 2005 , 4, 33-44	0.9	27
45	Comparison of Vascular α -Adrenoceptor Antagonism of Tamsulosin in Oral Controlled Absorption System (OCAS) and Modified Release (MR) Formulations. <i>European Urology Supplements</i> , 2005 , 4, 45-52	0.9	19
44	Cardiovascular Safety of the Oral Controlled Absorption System (OCAS) Formulation of Tamsulosin Compared to the Modified Release (MR) Formulation. <i>European Urology Supplements</i> , 2005 , 4, 53-60	0.9	23
43	The Development of the Oral Controlled Absorption System (OCAS \square): A New Improved Formulation of Tamsulosin. <i>European Urology Supplements</i> , 2005 , 4, 1-4	0.9	7
42	The Improved Cardiovascular Safety of Omnic (Tamsulosin) Oral Controlled Absorption System (OCAS \square). <i>European Urology Supplements</i> , 2005 , 4, 10-13	0.9	4
41	The Clinical Development of Omnic (Tamsulosin) Oral Controlled Absorption System (OCAS \square). <i>European Urology Supplements</i> , 2005 , 4, 5-9	0.9	5
40	Night Time Symptom Control with Omnic (Tamsulosin) Oral Controlled Absorption System (OCAS \square). <i>European Urology Supplements</i> , 2005 , 4, 14-16	0.9	7
39	The Oral Controlled Absorption System (OCAS \square): The Evolution of Tamsulosin for the Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH). <i>European Urology Supplements</i> , 2005 , 4, 20-22	0.9	1
38	Behaviour and transit of tamsulosin Oral Controlled Absorption System in the gastrointestinal tract. <i>Current Medical Research and Opinion</i> , 2006 , 22, 2323-8	2.5	16
37	Tamsulosin \square modified-release and oral-controlled absorption system formulations in the treatment of benign prostatic hyperplasia. <i>Therapy: Open Access in Clinical Medicine</i> , 2006 , 3, 237-246		7
36	Introduction and summary. <i>BJU International</i> , 2006 , 98, 1-2	5.6	54
35	Pharmacokinetic profile of tamsulosin OCAS. <i>BJU International</i> , 2006 , 98, 9-12	5.6	4
34	Efficacy and safety of tamsulosin OCAS. <i>BJU International</i> , 2006 , 98, 13-17	5.6	13
33	Comparison of the cardiovascular effects of tamsulosin oral controlled absorption system (OCAS) and alfuzosin prolonged release (XL). <i>European Urology</i> , 2006 , 49, 501-8; discussion 508-9	10.2	17
32	Tamsulosin. 2007 , 1-7		

31	Introduction and Conclusions. <i>European Urology Supplements</i> , 2007 , 6, 573-575	0.9	3
30	Impact of Tamsulosin OCAS on Energy of Patients with LUTS/BPH. <i>European Urology Supplements</i> , 2007 , 6, 594-599	0.9	
29	Nocturia and Tamsulosin OCAS. <i>European Urology Supplements</i> , 2007 , 6, 723-727	0.9	4
28	Tamsulosin MR and OCAS (modified release and oral controlled absorption system): current therapeutic uses. <i>Expert Opinion on Pharmacotherapy</i> , 2008 , 9, 813-24	4	4
27	Tamsulosin modified release and oral controlled absorption system in the management of lower urinary tract symptoms suggestive of benign prostatic hyperplasia. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2008 , 4, 771-82	5.5	2
26	Combined medical treatment using dutasteride and tamsulosin for lower urinary tract symptoms suggestive of benign prostatic hyperplasia. <i>Expert Opinion on Pharmacotherapy</i> , 2010 , 11, 2535-47	4	8
25	Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations. <i>Clinical Pharmacokinetics</i> , 2010 , 49, 177-88	6.2	37
24	Formulation variation and in vitro-in vivo correlation for a rapidly swellable three-layered tablet of tamsulosin HCl. <i>Chemical and Pharmaceutical Bulletin</i> , 2011 , 59, 529-35	1.9	10
23	Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin. <i>British Journal of Clinical Pharmacology</i> , 2011 , 72, 247-56	3.8	24
22	Poly(sebacic acid-co-ricinoleic acid) biodegradable carrier for delivery of tamsulosin hydrochloride. <i>Polymers for Advanced Technologies</i> , 2011 , 22, 114-118	3.2	3
21	The effect of food on the oral bioavailability of drugs: a review of current developments and pharmaceutical technologies for pharmacokinetic control. <i>Therapeutic Delivery</i> , 2012 , 3, 81-90	3.8	19
20	Determination of tamsulosin in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2012 , 909, 65-9	3.2	11
19	Pharmacoscintigraphy confirms consistent tamsulosin release from a novel triple-layered tablet. <i>International Journal of Pharmaceutics</i> , 2013 , 454, 41-6	6.5	5
18	New investigation of distribution imaging and content uniformity of very low dose drugs using hot-melt extrusion method. <i>International Journal of Pharmaceutics</i> , 2013 , 458, 245-53	6.5	27
17	Effects of food intake on the pharmacokinetic properties of mirabegron oral controlled-absorption system: a single-dose, randomized, crossover study in healthy adults. <i>Clinical Therapeutics</i> , 2013 , 35, 333-41	3.5	19
16	Intestinal absorption mechanism of mirabegron, a potent and selective β adrenoceptor agonist: involvement of human efflux and/or influx transport systems. <i>Molecular Pharmaceutics</i> , 2013 , 10, 1783-94	5.6	16
15	[Trade-offs in oral drug product development]. <i>Yakugaku Zasshi</i> , 2015 , 135, 229-35	0	
14	Interactions between medications employed in treating benign prostatic hyperplasia and food - A short review. <i>Biomedicine and Pharmacotherapy</i> , 2016 , 83, 1141-1145	7.5	9

13	Impact of Formulation on the Pharmacokinetic Profile of Dutasteride. <i>Clinical Drug Investigation</i> , 2016 , 36, 769-770	3.2	
12	Tamsulosin ?. 2017 ,		
11	Design and evaluation of transdermal delivery system containing tamsulosin hydrochloride. <i>Journal of Drug Delivery Science and Technology</i> , 2019 , 51, 524-534	4.5	2
10	Simultaneous HPLC determination of alfuzosin, tamsulosin and vardenafil in human plasma and pharmaceutical formulations using time programmed fluorescence detection. <i>Annales Pharmaceutiques Francaises</i> , 2019 , 77, 28-37	1.3	11
9	Factors Associated With Nocturia-Related Quality of Life in Men With Lower Urinary Tract Symptoms and Treated With Tamsulosin Oral Controlled Absorption System in a Non-Interventional Study. <i>Frontiers in Pharmacology</i> , 2020 , 11, 816	5.6	4
8	Specific pharmacokinetic aspects of the urinary tract. <i>Handbook of Experimental Pharmacology</i> , 2011 , 267-82	3.2	3
7	Quantification of tamsulosin in human plasma by high-performance liquid chromatography coupled with electrospray tandem mass spectrometry. <i>Acta Chromatographica</i> , 2010 , 22, 99-116	1.5	1
6	Tamsulosin - modified-release and oral-controlled absorption system formulations in the treatment of benign prostatic hyperplasia. <i>Therapy: Open Access in Clinical Medicine</i> , 2006 , 3, 237-246		2
5	Evolving Biopharmaceutics Perspectives for Hydrophilic Matrix Tablets: Dosage Form Blood Interactions and Dosage Form Gastrointestinal Tract Interactions. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2014 , 281-321	0.5	
4	A Review on Clinical Pharmacokinetics of Tamsulosin in Patients with Benign Prostatic Hyperplasia. <i>Jundishapur Journal of Chronic Disease Care</i> , 2016 , 6,	1.4	1
3	DataSheet_1.docx. 2020 ,		
2	DataSheet_2.docx. 2020 ,		
1	WYBRANE TECHNOLOGIE OPTIMALIZUJĄCE DOSTARCZANIE SUBSTANCJI CZYNNYCH W NOWOCZESNYCH POSTACIACH LEKU. 2009 , 7, 19-23		0